An Open Label Single Dose Study To Investigate Safety And Pharmacokinetics Of Maraviroc Following A Single Oral Dose Of 300 Mg Maraviroc (Two 150 Mg Maraviroc Commercial Tablets) Under Fasting Conditions In Healthy Male Japanese Volunteers.
Latest Information Update: 02 Dec 2010
At a glance
- Drugs Maraviroc (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 15 Nov 2010 ViiV Healthcare added in associations field as reported by ClinicalTrials.gov.
- 15 Nov 2010 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 16 May 2009 Actual patient number (12) added as reported by ClinicalTrials.gov.